Clinical Trials Logo

AV Block clinical trials

View clinical trials related to AV Block.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06197503 Recruiting - Clinical trials for Transcatheter Aortic Valve Implantation

Randomized Study of Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post TAVI

PHYSTAVIII
Start date: November 30, 2023
Phase: N/A
Study type: Interventional

Single-center randomized trial in patients with pacing indication (AV block) after TAVI (transfemoral aortic valve implantation) and LVEF> 50%, that aims to study the percentage of patients who improve at 12 months in a combined clinical endpoint.

NCT ID: NCT05856799 Recruiting - AV Block Clinical Trials

Danish Randomized Trial on Leadless vs Transvenous Pacing

DANVERS
Start date: August 25, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the quality of life, patient acceptance and exercise capacity with leadless compared to transvenous pacing in elderly patients with new-onset high-grade atrioventricular block. Consecutive patients with high-grade atrioventricular black and preserved sinus node function with indication for permanent pacemaker implantation according to the latest european guidelines, are included in a prospective, partly patient and accessor blinded and partly open label, 1:1 randomized combined parallel and cross-over trial to implantation with 1) a Micra AV Transcathter Pacing System or 2) an Azure XT DR dual chamber pacemaker.

NCT ID: NCT05650658 Recruiting - Heart Failure Clinical Trials

Left vs Left Randomized Clinical Trial

Start date: September 13, 2023
Phase: N/A
Study type: Interventional

The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with/anticipated >40% pacing who are already receiving current standard heart failure pharmacological therapy.

NCT ID: NCT04867460 Recruiting - Heart Failure Clinical Trials

Ultrasound-guided Venous Access for Pacemaker and Defibrillator Implants

TUFF
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The study will include patients scheduled for transvenous pacemaker- or implantable defibrillator surgery, where venous access is necessary for lead implantation. A 1:1 randomization will be performed to either standard access (at the discretion of the surgeon) or ultrasound-guided using a wireless vascular transducer (Siemens Freestyle). Primary outcome is mean time to vascular access. In addition, success rate, complication rate and total procedure time will be measured.

NCT ID: NCT04749836 Recruiting - AV Block Clinical Trials

Outcomes and Safety of Various Conduction System Pacing Methods

Start date: February 4, 2021
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to evaluate safety and clinical outcomes after different pacing approaches of conduction system pacing in a prospective registry.

NCT ID: NCT03556189 Recruiting - AV Block Clinical Trials

Atrioventricular Optimization for Dual Chamber Pacemaker

Start date: September 2015
Phase: N/A
Study type: Interventional

This study aims to examine the effect of atrioventricular synchrony in AV block patients who received permanent pacemaker. By achieving physiologic ventricular diastolic filling, adjustment of atrioventricular delay of pacemaker might affect the long term outcome of left ventricular function and remodelling. The investigators designed to randomize AV block patients who already have or anticipated to receive pacemaker, into two groups. Patients in intervention group undergo reprogramming AV delay of pacemaker to the best value to increase cardiac output measured by transthoracic echocardiogram and the patients in control group undergo routinely scheduled pacemaker programming. The primary endpoint is improvement of LV systolic function and the secondary endpoint is change in left ventricular volume, cardiac output, BNP, 6-minute walk capacity and NYHA class after one year.